Human drug abuse liability assessment: opioids and analgesics.

Methods are described for assessment of the abuse liability of opioids and analgesics. The methods developed by the USPHS Addiction Research Center for assessment of opioid abuse liability have served as the prototype for most currently used abuse liability assessment approaches. The general method is that of comparing the profile of effects of a test drug to the profiles of placebo and of a known drug of abuse. Drugs with profiles of activity similar to the known drug of abuse are considered pharmacologically equivalent and of similar abuse liability. Specific methods, including the Addiction Research Inventory, adjective- and visual analog rating scales, are described, as are methodological developments that have been introduced to improve the sensitivity of the procedures and to adapt them to modern circumstances. It is concluded that the profile-of-effects methodology has proven extremely useful and should remain a basic element in abuse liability assessments.

[1]  K. Preston,et al.  Evaluation of the abuse potential of the novel analgesic flupirtine maleate. , 1991, Drug and alcohol dependence.

[2]  K. Preston,et al.  Abuse potential and pharmacological comparison of tramadol and morphine. , 1991, Drug and alcohol dependence.

[3]  W. Bickel,et al.  Drug discrimination in human postaddicts: agonist-antagonist opioids. , 1989, The Journal of pharmacology and experimental therapeutics.

[4]  W K Bickel,et al.  Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. , 1988, The Journal of pharmacology and experimental therapeutics.

[5]  K. Preston,et al.  Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. , 1988, NIDA research monograph.

[6]  K. Preston,et al.  Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts. , 1987, The Journal of pharmacology and experimental therapeutics.

[7]  K. Preston,et al.  Comparison of intravenously administered methadone, morphine and heroin. , 1986, Drug and alcohol dependence.

[8]  K. Preston,et al.  Assessment of dezocine for morphine‐like subjective effects and miosis , 1985, Clinical pharmacology and therapeutics.

[9]  D. Jasinski,et al.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. , 1978, Archives of general psychiatry.

[10]  D. Jasinski,et al.  Assessment of the Abuse Potentiality of Morphinelike Drugs (Methods Used in Man) , 1977 .

[11]  D. Jasinski,et al.  Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man , 1971, Clinical pharmacology and therapeutics.

[12]  R. Hoeldtke,et al.  Effects of short‐ and long‐term administration of pentazocine in man , 1970, Clinical pharmacology and therapeutics.

[13]  D. Jasinski,et al.  The Use of the Polaroid CU Camera in Pupillography , 1967 .

[14]  W. Martin,et al.  Methods for evaluating addiction liability. (A) "Attitude" of opiate addicts toward opiate-like drugs. (B) a short-term "direct" addiction test. , 1961, The Journal of pharmacology and experimental therapeutics.

[15]  L. Kolb,et al.  CLINICAL STUDIES OF DRUG ADDICTION, III , 1938 .